The neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center discussed the reasons behind the use of quantitative EEG in assessing Cognition Therapeutics' Alzheimer agent CT1812. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"Theta power is a relatively robust measure of slow activity and connectivity that has been shown in a few larger trials in the past."
CT1812, developed by Cognition Therapeutics, is an orally delivered small molecule sigma-2 (σ-2) receptor modulator designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex. The σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble amyloid-ß oligomers, oxidative stress, and other stressors.
The SEQUEL study (NCT04735536) is an ongoing pivotal trial assessing the effects of CT1812 in a cohort of patients with mild-to-moderate Alzheimer disease (AD). Following a 28-day treatment period, patients undergo a 14-day washout and crossover into the other treatment arm, either CT1812 or placebo, for an additional 28 days. At the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting, held October 24-27, in Boston, Massachusetts, data from the study showed that CT1812-treated patients exhibited statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified electroencephalogram (EEG) parameters.
Presented by Williem de Haan, MD, PhD, the study also showed improvements in global relative theta power (P = .123) and in global relative alpha power (P = .149), as well as in connectivity, as assessed by alpha AECc (P = .034). de Haan, neurologist and senior research at the Amsterdam University Medical Centers’ Alzheimer Center, sat down with NeurologyLive® at the meeting to discuss the data and the reasons behind the use of EEG parameters in AD.